Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Inflammatory Bowel Diseases

Free Subscription 23.03.2026 6 Aliment Pharmacol Ther 1 Am J Gastroenterol 4 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 3 Dig Dis Sci 3 Gastroenterology 7 Inflamm Bowel Dis 1 J Clin Gastroenterol 5 J Crohns Colitis 1 J Gastroenterol 2 Minerva Gastroenterol (Torino) 1 Scand J Gastroenterol 3 Z Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. REJI R, Novak K
   Editorial: "Striding" Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Mar 17. doi: 10.1111/apt.70513.
   PubMed        
   
   
2. LIU C, He D, Wei A, Xu L, et al
   Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70632.
   PubMed        
   
   
3. KUMAR A, Patil A, Sharma V
   Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70624.
   PubMed        
   
   
4. SALUJA H, Chinnaratha MA
   Letter: Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
   Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70633.
   PubMed        
   
   
5. CARBERY I, Selinger CP
   Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty?
   Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70621.
   PubMed        
   
   
6. SAWARD G, Segal J
   Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis.
   Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70617.
   PubMed        
   
   

   
   Am J Gastroenterol

7. BAKER NM, Santiago-Soltero K, Anshelevich E, Ebriani J, et al
   Identifying key predictors of metastatic cutaneous Crohn's disease: a case-control study.
   Am J Gastroenterol. 2026 Mar 20. doi: 10.14309/ajg.0000000000004003.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

8. GUNEGUL Y, Keskin O, Kav T
   Sleep impairment in patients with ulcerative colitis: a cross-sectional assessment of clinical, inflammatory, metabolic and behavioral factors.
   BMC Gastroenterol. 2026 Mar 18. doi: 10.1186/s12876-026-04727.
   PubMed        
   
   
9. REDDY A, Burstiner LS, Patel N, Qadir N, et al
   Corticosteroid use, bone density screening, and the influence of insurance in patients with inflammatory bowel disease: a retrospective analysis.
   BMC Gastroenterol. 2026 Mar 17. doi: 10.1186/s12876-026-04717.
   PubMed        
   
   
10. ZHAO X, Zhang X
    ITPR1 mediates the PI3K/AKT/mTOR pathway to regulate cellular autophagy, affecting lipopolysaccharide-induced pediatric inflammatory bowel disease.
    BMC Gastroenterol. 2026 Mar 16. doi: 10.1186/s12876-026-04738.
    PubMed        
    
    
11. SUDHAKARAN SC, Wayland MT, Purushotham Y, Minchenberg SB, et al
    Beyond the bowel: novel comorbidity patterns in inflammatory bowel disease from the all of us research program.
    BMC Gastroenterol. 2026 Mar 14. doi: 10.1186/s12876-026-04732.
    PubMed        
    
    

    
    Clin Gastroenterol Hepatol

12. FAN D, Mao Y, Liang F, Liu Z, et al
    INTELCAPE: A Deep Learning-Powered System for Automated, High-Accuracy Crohn's Disease Diagnosis via Capsule Endoscopy.
    Clin Gastroenterol Hepatol. 2026 Mar 18:S1542-3565(26)00184.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

13. AXI LB, Wang YF
    Misdiagnosis of Intestinal Amoebiasis as Inflammatory Bowel Disease: Alert Cases and Construction of Diagnostic Pathways in Endemic Areas.
    Dig Dis Sci. 2026 Mar 18. doi: 10.1007/s10620-026-09819.
    PubMed        
    
    
14. KHAN R
    Comment on "Type 1 Dolichocolon as a Potential Anatomic Co?morbidity in Children with Perianal Crohn's Disease".
    Dig Dis Sci. 2026 Mar 17. doi: 10.1007/s10620-026-09840.
    PubMed        
    
    
15. LAN N, Gupta S, Hamilton MJ
    Cut or Treat: Surgery or Medical Management of Patients with Crohn's Disease and Evidence of Acute Appendicitis.
    Dig Dis Sci. 2026 Mar 14. doi: 10.1007/s10620-026-09802.
    PubMed         Abstract available
    
    

    
    Gastroenterology

16. SCARALLO L, Alvisi P, Bramuzzo M, Domanico A, et al
    Intestinal Ultrasound Scan in Acute Severe Ulcerative Colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of ESPGHAN.
    Gastroenterology. 2026 Mar 16:S0016-5085(26)00232.
    PubMed         Abstract available
    
    
17. VERSTOCKT S, Schwarzler J, Willeit P, Bislenghi G, et al
    Identification of a druggable target that predicts postoperative Crohn's disease recurrence.
    Gastroenterology. 2026 Mar 16:S0016-5085(26)00233.
    PubMed         Abstract available
    
    
18. BUSKENS CJ, Bemelman WA
    Interpreting a Negative Trial in Complex Perianal Crohn's Disease: The End of Allogenic stem cell treatment for fistula patients?
    Gastroenterology. 2026 Mar 16:S0016-5085(26)00244.
    PubMed        
    
    

    
    Inflamm Bowel Dis

19. KAKKAR R, Byrne MF
    Artificial intelligence and the future of inflammatory bowel disease trial recruitment: from bottleneck to breakthrough.
    Inflamm Bowel Dis. 2026 Mar 13:izag036. doi: 10.1093.
    PubMed        
    
    
20. XIA J, Zhang Y
    A methodological concern regarding small-sample propensity score matching and overfitting in the study of postoperative biologic strategies for Crohn's disease.
    Inflamm Bowel Dis. 2026 Mar 13:izag024. doi: 10.1093.
    PubMed        
    
    
21. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    Response to Letter to the Editor: "Enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis".
    Inflamm Bowel Dis. 2026 Mar 14:izag034. doi: 10.1093.
    PubMed        
    
    
22. SHI H, Zhang S, Peng Y
    Letter to the editor: enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis.
    Inflamm Bowel Dis. 2026 Mar 14:izag033. doi: 10.1093.
    PubMed        
    
    
23. GUO Q, Wang Q, Chen J, Lu M, et al
    Impact of visceral adipose tissue and skeletal muscle on early and long-term biologic treatment failure in Crohn's disease: A multicenter retrospective cohort study.
    Inflamm Bowel Dis. 2026 Mar 16:izag023. doi: 10.1093.
    PubMed         Abstract available
    
    
24. TAMURA A, Fujii T, Fujiwara S, Maeyashiki C, et al
    Efficacy and Rapid Response of Ustekinumab for Hospitalized Patients With Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2026 Mar 16:izaf326. doi: 10.1093.
    PubMed        
    
    
25. GHONEIM S, Dicken Q, Omede M, Harris H, et al
    Disease reprogression following surgical resection in Crohn disease.
    Inflamm Bowel Dis. 2026 Mar 19:izag035. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

26. ELDESOUKI MH, Elfert K, Alkasabrah O, Elsharkawy MM, et al
    Comparative Effectiveness of Upadacitinib Versus Ustekinumab in Ulcerative Colitis Patients With Prior Tumor Necrosis Factor Inhibitor Exposure: A matched Cohort Study.
    J Clin Gastroenterol. 2026 Mar 16. doi: 10.1097/MCG.0000000000002354.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

27. MAGRO F, Ministro P, de Sousa HT, Roseira J, et al
    Distinct hepcidin patterns in Crohn's disease and ulcerative colitis: links to iron homeostasis and inflammatory activity.
    J Crohns Colitis. 2026;20:jjag023.
    PubMed         Abstract available
    
    
28. DE GREEF E, Turner D, Kierkus J, Korczowski B, et al
    Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.
    J Crohns Colitis. 2026;20:jjag011.
    PubMed         Abstract available
    
    
29. DEMIRLI ATICI S, Canda AE, Terzi MC
    Anatomy is not activity: rethinking MRI fistula volume in perianal Crohn's disease.
    J Crohns Colitis. 2026 Mar 17:jjag031. doi: 10.1093.
    PubMed        
    
    
30. CHRISTENSEN HS, Larsen L, Lees CW, Bogsted M, et al
    Real-world evidence on medication patterns in inflammatory bowel disease the first decade after diagnosis.
    J Crohns Colitis. 2026;20:jjag025.
    PubMed         Abstract available
    
    
31. JOHANSEN I, Hagen MC, Lokkeberg ST, Aabrekk TB, et al
    Anxiety and depression in newly diagnosed patients with inflammatory bowel disease (the IBSEN III study) compared with the general population in Norway.
    J Crohns Colitis. 2026;20:jjag021.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

32. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

33. VITELLO A, Nardone OM, Calabrese G, Carnazzo SM, et al
    The role of fecal calprotectin in assessing response to advanced medical treatments for inflammatory bowel diseases: a review of the literature.
    Minerva Gastroenterol (Torino). 2026;72:51-59.
    PubMed         Abstract available
    
    
34. MIGLIORE G, Troisi S, Petito V, Masi L, et al
    Modulation of IL33/ST2 axis and mucosal healing in IBD: state of the art and future perspectives.
    Minerva Gastroenterol (Torino). 2026;72:91-103.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

35. DENBY K, Connelly EDS, Glerup H, Ostgard R, et al
    Translation and cross-cultural adaptation of the Identification of Spondyloarthritis Questionnaire (IBIS-Q) into Danish for patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2026 Mar 18:1-9. doi: 10.1080/00365521.2026.2645081.
    PubMed         Abstract available
    
    

    
    Z Gastroenterol

36. STEIN J, Schroeder O, Tessmer L, Muller E, et al
    [Obesity meets Inflammatory Bowel Disease - a Double Whammy? A narrative Review].
    Z Gastroenterol. 2026;64:283-299.
    PubMed         Abstract available
    
    
37. ALEXANIDOU E, Horning A, de Laffolie J, Schmidt-Choudhury A, et al
    [Correction: Crohn's Disease Exclusion Diet (CDED) and partial enteral nutrition (PEN) for remission induction in children and adolescents with Crohn's Disease - Updated statement from the CEDATA and Nutrition/Dietetics/Nutritional Medicine Working Gr
    Z Gastroenterol. 2026;64:e85.
    PubMed        
    
    
38. SCHNOY E, Dignass A, Gaskins M, Kucharzik T, et al
    Correction: From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis.
    Z Gastroenterol. 2025;63:e668-e669.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum